These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

527 related articles for article (PubMed ID: 34146514)

  • 21. Neuroprotection in Parkinson's disease: myth or reality?
    Voss T; Ravina B
    Curr Neurol Neurosci Rep; 2008 Jul; 8(4):304-9. PubMed ID: 18590614
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Progression of motor symptoms in Parkinson's disease.
    Xia R; Mao ZH
    Neurosci Bull; 2012 Feb; 28(1):39-48. PubMed ID: 22233888
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Assessment of the progression of Parkinson's disease: a metabolic network approach.
    Eckert T; Tang C; Eidelberg D
    Lancet Neurol; 2007 Oct; 6(10):926-32. PubMed ID: 17884682
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Precision medicine in Parkinson's disease: emerging treatments for genetic Parkinson's disease.
    Schneider SA; Alcalay RN
    J Neurol; 2020 Mar; 267(3):860-869. PubMed ID: 31974807
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neuroprotection in Parkinson's disease: an elusive goal.
    Biglan KM; Ravina B
    Semin Neurol; 2007 Apr; 27(2):106-12. PubMed ID: 17390255
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The evidence for disease modification in Parkinson's disease.
    Lew MF
    Int J Neurosci; 2011; 121 Suppl 2():18-26. PubMed ID: 22035026
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Parkinson's: treating the symptoms.
    Lindahl DA
    Br J Nurs; 2011 Jul 28-Aug 4; 20(14):852, 854-7. PubMed ID: 21841671
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The natural history of Parkinson's disease.
    Poewe W
    J Neurol; 2006 Dec; 253 Suppl 7():VII2-6. PubMed ID: 17131223
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Disease Modification in Parkinson's Disease: Current Approaches, Challenges, and Future Considerations.
    Lang AE; Espay AJ
    Mov Disord; 2018 May; 33(5):660-677. PubMed ID: 29644751
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Therapeutic innovation in Parkinson's disease: a 2020 update on disease-modifying approaches.
    Colombo D; Pnevmatikou P; Melloni E; Keywood C
    Expert Rev Neurother; 2020 Oct; 20(10):1047-1064. PubMed ID: 32758042
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Insights from late-onset familial parkinsonism on the pathogenesis of idiopathic Parkinson's disease.
    Volta M; Milnerwood AJ; Farrer MJ
    Lancet Neurol; 2015 Oct; 14(10):1054-64. PubMed ID: 26376970
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Symptoms and medications change patterns for Parkinson's disease patients stratification.
    Valmarska A; Miljkovic D; Konitsiotis S; Gatsios D; Lavrač N; Robnik-Šikonja M
    Artif Intell Med; 2018 Sep; 91():82-95. PubMed ID: 29803610
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of animal models of Parkinson's disease for neuroprotective strategies.
    Emborg ME
    J Neurosci Methods; 2004 Oct; 139(2):121-43. PubMed ID: 15488225
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Parkinson's: symptoms, treatments and research.
    Heisters D
    Br J Nurs; 2011 May 13-26; 20(9):548-54. PubMed ID: 21647015
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Understanding Epigenetic Alterations in Alzheimer's and Parkinson's Disease: Towards Targeted Biomarkers and Therapies.
    Ciceri F; Rotllant D; Maes T
    Curr Pharm Des; 2017; 23(5):839-857. PubMed ID: 28120717
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neurobiology and treatment of Parkinson's disease.
    Schapira AH
    Trends Pharmacol Sci; 2009 Jan; 30(1):41-7. PubMed ID: 19042040
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunization therapies for Parkinson's disease: state of the art and considerations for future clinical trials.
    Antonini A; Bravi D; Sandre M; Bubacco L
    Expert Opin Investig Drugs; 2020 Jul; 29(7):685-695. PubMed ID: 32419521
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Therapies to Slow, Stop, or Reverse Parkinson's Disease.
    Foltynie T; Langston JW
    J Parkinsons Dis; 2018; 8(s1):S115-S121. PubMed ID: 30584162
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Precompetitive Data Sharing as a Catalyst to Address Unmet Needs in Parkinson's Disease.
    Stephenson D; Hu MT; Romero K; Breen K; Burn D; Ben-Shlomo Y; Bhattaram A; Isaac M; Venuto C; Kubota K; Little MA; Friend S; Lovestone S; Morris HR; Grosset D; Sutherland M; Gallacher J; Williams-Gray C; Bain LJ; Avilés E; Marek K; Toga AW; Stark Y; Forrest Gordon M; Ford S
    J Parkinsons Dis; 2015; 5(3):581-94. PubMed ID: 26406139
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Calcium Channel Antagonists as Disease-Modifying Therapy for Parkinson's Disease: Therapeutic Rationale and Current Status.
    Swart T; Hurley MJ
    CNS Drugs; 2016 Dec; 30(12):1127-1135. PubMed ID: 27826740
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.